pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·6h ago·1 min read
save

Lundbeck plans US headquarters move to Boston to boost neuroscience R&D

Sep 25, 2026·read at Fierce Biotech ↗Neutral

Lundbeck, a Danish pharmaceutical company focused on neuroscience, announced it will relocate its U.S. operations to Boston.

The move is part of a broader strategy to concentrate R&D on increasingly specialized neuroscience targets, leveraging Boston's dense biopharma ecosystem.

By establishing its U.S. headquarters in a leading biotech hub, Lundbeck aims to accelerate innovation and collaboration with academic and industry partners.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “Lundbeck to move US digs to Boston as it eyes bigger innovation frontiers”

read at Fierce Biotech ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING

related stories

  • May 4Opinion: Are blue zones real? Answering that question is harder than everSTAT
  • May 2Federal appeals court blocks mailing of abortion pill mifepristoneSTAT
  • May 1Arvinas’ ‘Protac’ breast cancer drug cleared by FDABioPharma Dive
  • Apr 30Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstoodSTAT
  • Apr 30Merck still sees ‘compelling’ outlook for Terns leukemia drugBioPharma Dive